11/21
08:05 am
lsta
Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
11/19
08:41 am
lsta
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year' [Yahoo! Finance]
Medium
Report
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year' [Yahoo! Finance]
11/19
08:30 am
lsta
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
Medium
Report
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
11/13
02:26 am
lsta
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... [Yahoo! Finance]
Medium
Report
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... [Yahoo! Finance]
11/12
04:05 pm
lsta
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
09:29 am
lsta
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration [Yahoo! Finance]
Low
Report
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration [Yahoo! Finance]
11/6
09:23 am
lsta
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Low
Report
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
11/6
08:30 am
lsta
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
High
Report
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
11/1
02:04 pm
lsta
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
High
Report
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
10/31
08:30 am
lsta
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
Low
Report
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
10/28
08:30 am
lsta
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Medium
Report
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
10/3
08:00 am
lsta
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
Low
Report
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
9/18
08:05 am
lsta
Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
9/17
08:00 am
lsta
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
Medium
Report
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
9/9
08:00 am
lsta
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
Low
Report
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
9/5
08:00 am
lsta
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Medium
Report
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma